Endogenous carriers and ligands in non-immunogenic site-specific drug delivery

Advanced Drug Delivery Reviews

Volumn 43, Issue 2-3, 2000, Pages 101-164

  Vyas, S P ^a   Sihorkar, V ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Bio ligand; Endogenous; Receptor; Serum component; Site specificity; Targeting

Indexed keywords

CYTOLOGY; IMMUNOLOGY;

BIOLIGANDS; ENDOGENOUS SERUM;

CONTROLLED DRUG DELIVERY;

ANTIBODY; APOLIPOPROTEIN; CHIMERIC ANTIBODY; CYTOKINE; DRUG CARRIER; DRUG RECEPTOR; FOLIC ACID; GROWTH FACTOR; IMMUNOGLOBULIN; INSULIN; LIGAND; LIPOPROTEIN; OKT 4; PEPTIDE HORMONE; PROTEIN ANTIBODY; SERUM ALBUMIN; TRANSFERRIN; TUFTSIN; TUMOR NECROSIS FACTOR;

ANTIGEN PRESENTATION; BIOCOMPATIBILITY; CANCER CELL; COLLOID; DRUG DELIVERY SYSTEM; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; HUMAN; IMMUNOGENICITY; LIGAND BINDING; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NONHUMAN; OPSONIZATION; PHAGOCYTOSIS; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; REVIEW; SERUM;

ANIMALS; BLOOD PROTEINS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; HUMANS; LIGANDS; PEPTIDES; SIGNAL TRANSDUCTION;

EID: 0034734960     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(00)00067-3     Document Type: Article

References (277)

1. Patel H.M. Serum opsonins and liposomes: their interaction and opsonophagocytosis. Crit. Rev. Ther. Drug Carrier Syst. 9:1992;39-90.
2. Moghimi S.M., Patel H.M. Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system - the concept of tissue specificity. Adv. Drug Deliv. Rev. 32:1998;45-60.
3. Ogawara K., Yoshida M., Kubo J., Mnishikawa M., Takakura Y., Hashida M., Higaki K., Kimura T. Mechanism of hepatic disposition of polystyrene microspheres in rats: effects of serum depend on the size of microspheres. J. Control. Release. 61:1999;241-250.
4. Tortora G.J., Funke B.R., Case C.L. Microbiology: An Introduction. 6th Edition:1998;Addison Wesley Longman, CA. 456 pp.
5. Diamantstein T., Osawa H., Mouzaki A., Josimovic A.O. Regulation of interleukin-2 receptor expression and receptor release. Mol. Immunol. 23:1986;1165-1167.
6. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
7. Wagner E., Curiel D., Cotton M. Delivery of drugs, proteins and genes into cells using transferrin as a ligand for receptor-mediated endocytosis. Adv. Drug Deliv. Rev. 14:1994;113-135.
8. Pieters M.N., Schouten D., Van Berkel Th.J. In vitro and in vivo evidence for the role of HDL in reverse cholesterol transport. Biochim. Biophys. Acta. 1225:1994;125-134.
9. Kuby J. Immunology. 2nd Edition:1994;W.H. Freeman, New York.
10. Molema G., Meijer D.K.F. Targeting of drugs to various blood cell using (neo)-glycoproteins, antibodies and other protein carriers. Adv. Drug Deliv. Rev. 14:1994;25-50.
11. Friden P.M. Utilization of endogenous cellular transport system for the delivery of therapeutic across the blood-brain barrier. J. Control. Release. 46:1996;117-128.
12. Forssen E., Willis M. Ligand-targeted liposomes. Adv. Drug Deliv. Rev. 29:1998;249-271.
13. Utsumi S., Shinomiya H., Minami J., Sonoda S. Inhibition of phagocytosis by erythrocyte membrane sialoglycoprotein on target liposomes. Immunology. 49:1983;113-120.
14. Yamauchi H., Yano T., Kato T., Tanaka I., Nakabayashi S., Higashi K., Miyoshi S., Yamada H. Effects of sialic acid derivative on long circulation time and tumor concentration of liposomes. Int. J. Pharm. 113:1995;141-148.
15. Vyas S.P., Dixit V.K. Pharmaceutical Biotechnology. 1st Edition:1998;395-396 CBS, New Delhi.
16. Bijsterbosch M.K., van Berkel T.J. Native and modified lipoproteins as drug delivery systems. Adv. Drug Deliv. Rev. 5:1990;231-251.
17. Rijnboutt S., Jansen G., Strous G.J. Endocytosis of GPI-linked membrane folate receptor-alpha. J. Cell Biol. 132:1996;35.
18. Jeon S.I., Lee J.H., Andrade J.D., De Gennes P.G. Protein-surface interactions in the presence of polyethylene oxide. I. Simplified theory. J. Colloid Interface Sci. 142:1991;149-158.
19. Jeon S.I., Lee J.H., Andrade J.D. Protein-surface interactions in the presence of polyethylene oxide. II. Effect of protein size. J. Colloid Interface Sci. 142:1991;159-166.
20. Gee B., Warhol M.J., Roth J. Use of an anti-horseradish peroxidase antibody gold complex in the ABC technique. J. Histochem. Cytochem. 39:1991;863-867.
21. Scherphof G.L., Crommellin D.J.A. Cells involved in removing liposomes from the blood circulation: why are they so special? J. Liposome Res. 6:1996;19-31.
22. Panagi Z., Avgoustakis K., Evangelatos G., Ithakissios D.S. In vitro binding of HAS, IgG and HDL on liposomes of different composition and its correlation with the BLOOD/RES ratio of liposomes. Int. J. Pharm. 176:1999;203-207.
23. Shahrokh Z., Nichols A.V. Particle-size inter-conversion of human low-density lipoproteins during incubation of plasma with phosphatidylcholine vesicles. Biochem. Biophys. Res. Commun. 108:1982;888.
24. Comisky S.J., Heath T.D. Serum-induced leakage of negatively charged liposomes at nanomolar lipid concentrations. Biochemistry. 29:1990;3636.
25. Bonte F., Juliano R.L. Interaction of liposomes with serum proteins. Chem. Phys. Lipids. 40:1986;359-372.
26. Absolom D.R. Opsonins and dysopsonins: an overview. Methods Enzymol. 132:1986;281-318.
27. Moghimi S.M., Patel H.M. Differential properties of organ-specific serum opsonins for liver and spleen macrophages. Biochim. Biophys. Acta. 984:1989;379-383.
28. Tomlinson E., Burger J.J. Monolithiac albumin particles as drug carrier systems. Illum L., Davis S.S. Polymers in Controlled Drug Delivery. 1987;25-48 Wright, Bristol.
29. Moghimi S.M., Muir I.S., Illum L., Davis S.S., Kolb-Bachofen V. Coating particles with a block co-polymer (poloxamine-908) suppresses opsonization but permits the activity of dysopsonins in the serum. Biochim. Biophys. Acta. 1179:1993;157-165.
30. Bisgaier C.L., Siebenkas M.V., Williams K.J. Effect of apo-lipoproteins A-IV and A-I on the uptake of phospholipid liposomes by hepatocytes. J. Biol. Chem. 264:1989;862.
31. Fridkin M., Gottlieb P. Tuftsin, Thr-Lys-Pro-Arg. Anatomy of an immunologically active peptide. Mol. Cell. Biochem. 41:1981;73-97.
32. Bumrah R., Patel H.M. Opsonic effect of globulins on phagocytosis of liposomes by bone marrow cells. Biochem. Soc. Trans. 22:1994;86S.
33. Matsushita M., Endo Y., Taira S., Sato Y., Fujita T., Ichikawa N., Nakata M., Mizuochi T. A novel human serum lectin with collagen- and fibrinogen-like domains that function as an opsonin. J. Biol. Chem. 271:1996;2448-2454.
34. Muller R.H., Ruhl D., Luck M., Paulke B.R. Influence of fluorescent labelling of polystyrene particles on phagocytic uptake, surface hydrophilicity, and plasma protein adsorption. Pharm. Res. 14:1997;18-24.
35. Luck M., Schroder W., Paulke B.R., Muller R.H. Identification plasma proteins adsorbed on polystyrene model particles. Proc. Int. Symp. Control. Release Bioact. Mater. 24:1997;849-850.
36. Bucke W.E., Leitzke S., Diederichs J.E., Borner K., Hahn H., Ehlers S., Muller R.H. Surface-modified amilacin-liposomes: organ distribution and interaction with plasma proteins. J. Drug Targeting. 5:1998;99-108.
37. Luck M., Paulke B.R., Sebroder W., Blunk T., Muller R.H. Analysis of plasma protein adsorption on polymeric nanoparticles with different surface characteristics. J. Biomed. Mater. Res. 39:1998;478-485.
38. Luck M., Schroder W., Paulke B.R., Blunk T., Muller R.H. Complement activation by model drug carriers for intravenous application: determination by two-dimensional electrophoresis. Biomaterials. 20:1999;2063-2068.
39. Brynda E., Cepalova N.A., Stol M. Equilibrium adsorption of human serum albumin and human fibrinogen on hydrophobic and hydrophilic surfaces. Biomed. Mater. Res. 18:1984;685-693.
40. Ogawara K., Yoshida M., Takakura Y., Hashida M., Higaki K., Kimura T. Interaction of polystyrene microspheres with liver cells: roles of membrane receptors and serum proteins. Biochim. Biophys. Acta. 1472:1999;165-172.
41. Lasic D.D. Recent developments in medical applications of liposomes: sterically stabilized liposomes in cancer therapy and gene delivery in vivo. J. Control. Release. 48:1997;203.
42. Scherphof G.L., Kamps J.A.A.M. Receptor versus non-receptor mediated clearance of liposomes. Adv. Drug Deliv. Rev. 32:1998;81-97.
43. Reddy J.A., Low P.S. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit. Rev. Ther. Drug Carrier Syst. 15:1998;587-627.
44. Orlinick J.R., Chao M.V. TNF-related ligands and their receptors. Cell. Signal. 10:1998;543-551.
45. Singh M. Transferrin as a targeting ligand for liposomes and anti-cancer drugs. Curr. Pharm. Des. 5:1999;443-451.
46. Senekowitsch-Schmidtke R. Binding of EGF peptide and EGF receptor antibodies and its fragments in different tumor models. Hybridoma. 18:1999;29-35.
47. Schwartz A.L. Receptor cell biology: receptor-mediated endocytosis. Paediatr. Res. 38:1995;835.
48. Hasida M., Hirabyayashi H., Nishikawa M., Takakura Y. Targeted delivery of drugs and proteins to the liver via receptor mediated endocytosis. J. Control. Release. 46:1997;129-137.
49. Rihova B. Receptor-mediated targeted drug or toxin delivery. Adv. Drug Deliv. Rev. 29:1998;273-289.
50. Wu G.Y., Wu C.H. Receptor-mediated delivery of foreign genes to hepatocytes. Adv. Drug Deliv. Rev. 29:1998;243-248.
51. Mostov K.E. Transepithelial transport of immunoglobulins. Annu. Rev. Immunol. 12:1994;63-84.
52. Mostov K.E., Cardone M.H. Regulation of protein traffic in polarized epithelial cells. BioEssays. 17:1995;129-138.
53. Ferkol T., Kaetzel C.S., Davis P.B. Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest. 92:1993;2394-2400.
54. Ellis J.A., Luzio J.P. Identification and characterization of a novel protein (p. 137) which transcytoses bidirectionally in Caco-2 cells. J. Biol. Chem. 270:1995;20717.
55. Robinson M.S. The role of clathrin, adaptors and dynamin in endocytosis. Curr. Opin. Cell Biol. 6:1994;538-544.
56. Trowbridge L.S., Collawan J.F., Hopkins C.R. Signal-dependent membrane protein trafficking in the endocytic pathway. Annu. Rev. Cell Biol. 9:1993;129-161.
57. Lamaze C., Schmid S.L. The emergence of clathrin-independent pinocytic pathways. Curr. Opin. Cell Biol. 7:1995;573-580.
58. Anderson R.G.W. Potocytosis of small molecules and ions by caveolae. Trends Cell Biol. 3:1993;69-72.
59. Hewlett L.J., Prescott A.R., Watts C.J. J. Cell Sci. 124:1994;689.
60. Whitney J.A., Gomez M., Sheff D., Kreis T.E., Mellman I. Cytoplasmic coat proteins involved in endosome function. Cell. 83:1995;703-713.
61. Gruenberg J., Griffiths G., Howell K.E. Characterization of the early endosome and putative endocytic carrier vesicles in vivo and with an assay of vesicle fusion in vitro. J. Cell Biol. 108:1989;1301.
62. Stoovogel W., Strous G.J., Geuze H.J., Oorsschot V., Schwartz A.L. Late endosome derive from early endosome by maturation. Cell. 65:1991;417.
63. Kato Y., Seita T., Kuwabara T., Sugiyama Y. Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: use of RME as a drug delivery system. J. Control. Release. 39:1996;191-200.
64. Stenseth K., Thyberg P. Monensin and chloroquine inhibit transfer to lysosomes of endocytosed macromolecules in cultured mouse peritoneal macrophages. Eur. J. Cell Biol. 49:1989;326.
65. Marsh M. The entry of enveloped viruses into cells by endocytosis. Biochim. J. 218:1984;110.
66. FitzGerald D.J., Waldmann T.A., Willingham M.C., Pastan I. Pseudomonas exotoxin-anti TAC: cell specific immunotoxin active against cells expressing the human T-cell growth factor receptor. J. Clin. Invest. 74:1984;966.
67. Hamm-Alvarez S.F. Molecular motors and their role in membrane traffic. Adv. Drug Deliv. Rev. 29:1998;229-242.
68. Langford G.M. Actin- and microtubule-dependent organelle motors: inter-relationships between the two motility systems. Curr. Opin. Cell Biol. 7:1995;82.
69. Fukuta M., Okada H., Linuma S., Yanai S., Toguchi H. Insulin fragments as a carrier for peptide delivery across the blood brain barrier. Pharm. Res. 11:1994;1681.
70. Hager G.L., Smith C.L., Fragoso G., Wolford R., Walker D., Barsony J., Htun H. Intranuclear trafficking and gene targeting by members of the steroid/nuclear receptor superfamily. J. Steroid Biochem. Mol. Biol. 65:1998;125-132.
71. Menrad A., Thierauch K.H., Martiny-Baron G., Siemeister G., Schimer M., Schneider M.R. Novel antibodies directed against the extracellular domain of the human VEGF-receptor type II. Hybridoma. 16:1997;465-471.
72. Sarti P., Ginobbi P., D’Agostino I., Arancia G., Lendaro E., Molinari A., Ippoliti R., Citro G. Liposomal targeting of leukemia HL 60 cells induced by transferrin-receptor endocytosis. Biotechnol. Appl. Biochem. 24:1996;269.
73. Firestone R.A. Low-density lipoprotein as a vehicle for targeting anti-tumor compounds to cancer cells. Bioconjugate Chem. 5:1994;105-113.
74. Brandley B.K., Kiso M., Abbas S., Nicard P., Srivastava O., Foxall C., Oda Y., Hasegawa A. Structure-function studies on selectins carbohydrate ligands. Modification to fucose, sialic acid and sulfate as a sialic acid replacement. Glycobiology. 3:1993;633-639.
75. Seymour L.W. Soluble polymers for lectin-mediated targeting. Adv. Drug Deliv. Rev. 14:1994;89.
76. Molema G., Lou F., de Leij F.M.H., Meijer D.K.F. Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy. Pharm. Res. 14:1997;2-10.
77. Meijer D.K.F., Jansen R.W., Molema G. Drug targeting for anti-viral agents: options and limitations. Antiviral Res. 18:1992;215-258.
78. Brandley B.K., Swiedler S.J., Robbins P.W. Carbohydrate ligands of the LEC cell adhesion molecules. Cell. 63:1990;861-863.
79. Steinhoff G., Behrend M., Schrader B., Pichlmayr R. Intercellular immune adhesion molecules in human liver transplants: overview on expression patterns of leukocyte receptors and ligand molecules. Hepatology. 18:1993;440.
80. Rosen S.D., Bertozzi C.R. The selectins and their ligands. Curr. Opin. Cell Biol. 6:1994;663.
81. Berg E.L., Goldstein L.A., Picker L.J., Streeter P.R., Jutilla M.A., Bergatze R.F., Zhou D.F.H., Butcher E.C. Lymphocyte homing receptors and vascular addressins. Welplay J.K., Jaworski E. Glycobiology. 1990;91 Wiley-Liss, New York.
82. Frenette P.S., Wagner D.D. Adhesion molecules - Part I. New Engl. J. Med. 334:1996;1526-1529.
83. Frenette P.S., Wagner D.D. Adhesion molecules - Part II. New Engl. J. Med. 335:1996;43-45.
84. Lafrenie R.M., Yamada K.M. Integrin dependent signal transduction. J. Cell. Biochem. 61:1996;543-544.
85. Halvorson M.J., Coligan J.E., Sturmhofel K. The vitronectin receptor (alpha v beta 30) as an example for the role of integrins in T lymphocyte stimulation. Immunol. Res. 15:1996;16-29.
86. Bevilacqua M.P., Nelson R.M. Selectins. J. Clin. Invest. 91:1993;379-387.
87. Bevilacqua M.P., Nelson R.M., Mannori G., Cecconi O. Endothelial-leucocyte adhesion molecules in human disease. Annu. Rev. Med. 45:1994;361-378.
88. Lasky L.A. Selectins - Interpreters of cell-specific carbohydrate information during inflammation. Science. 258:1992;964-969.
89. Harding C.V., Gueze H.J. Antigen processing and intracellular traffic of antigen and MHC molecules. Curr. Opin. Cell Biol. 5:1993;596-605.
90. Gregoriadis G., McCormack B., Obrenovic M., Saffie R., Perle Y. Liposome-mediated DNA vaccination. Proceedings of the 2nd International Symposium on Advances in Technology and Business Potential of Novel Drug Delivery Systems, Goa, India:1999;93.
91. Hachia H.L., Takayama S., White M.F., King G.L. Regulation of insulin receptor internalization in vascular endothelial cells by insulin and phorbol ester. J. Biol. Chem. 262:1987;6417.
92. Hiratsuka S., Minowa O., Kuno J., Noda T., Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA. 94:1998;9349.
93. Nyomba B.L., Ossowski V.M., Bogardus C., Mott D.M. Insulin-sensitive tyrosine kinase: relationship with in vivo insulin action in humans. Am. J. Physiol. 58:1990;E964.
94. Ostro M.J. Liposomes: From Biophysics To Therapeutics. 1987;Marcel Dekker, New York.
95. Feener E.P., King G.L. The biochemical and physiological characteristics of receptors. Adv. Drug Deliv. Rev. 29:1998;197-213.
96. Timmermans P.B.M.W.M., Wong P.C., Chiu A.T., Herblin W.F.B., Cairni P., Lee R.J., Wexler R.R., Saye J.A.S., Smith R.D. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45:1993;205.
97. McConathy W.J., Alaupovic P. Isolation and characterization of apoproteins. Segrest J.P., Alka J.J. Methods in Enzymology. 1986;128, 297 Academic Press, Orlando, FL.
98. Salter A.M., Brindley D.N. The biochemistry of lipoproteins. J. Inherit. Metab. Dis. 11:1988;4.
99. Jaitely V., Kanaujia P., Vyas S.P. Lipoproteins: their potential as endogenous target oriented novel drug delivery system. Indian J. Exp. Biol. 35:1997;212-218.
100. Vyas S.P., Jaitely V., Kanaujia P. Self-assessing supramolecular biovectors: a new dimension in novel drug delivery systems. Pharmazie. 52:1997;259-267.
101. Wilson J.M., Grossman M., Cabrera J.A., Wu C.H., Wu G.Y. A novel mechanism for achieving transgene persistence in vivo after somatic gene transfer into hepatocytes. J. Biol. Chem. 267:1992;11483.
102. Wilson J.M., Grossman M., Wu C.H., Chowdhary N.R., Wu G.Y., Chowdhary J.R. Hepatocyte-directed gene transfer in vivo leads to transient improvement of hepatocholesterolemia in LDL-receptor deficient rabbits. J. Biol. Chem. 267:1992;963.
103. van Berkel Th.C., Kruij K., Kempen H. Specific targeting of HDL to liver hepatocytes by incorporation of a Tris-galactoside terminated cholesterol derivative. J. Biol. Chem. 260:1985;12203-12207.
104. Bijsterbosch M.K., Schouten D., van Berkel Th.J. Synthesis of the dioleoyl derivative of iododeoxyuridine and its incorporation into reconstituted high density lipoprotein particles. Biochemistry. 33:1994;14073-14080.
105. Pitas R.E., Boyles J., Mahley R.W. Uptake of chemically modified low-density lipoproteins in vivo is mediated by specific endothelial cells. J. Cell Biol. 100:1985;103-117.
106. Blomhoff R., Drevon C.A., Eskwild W., Helgerud P., Norum K.R., Berg T. Clearance of acetyl low-density lipoproteins by rat liver endothelial cells. J. Biol. Chem. 259:1984;1658-1664.
107. Bijsterbosch M.K., Ziere G.L., van Berkel Th.J. Acetylated low-density lipoproteins: a potential carrier for site-specific delivery of drugs to Kupffer cells. Mol. Pharmacol. 36:1989;484-489.
108. Nishikawa K., Arai H., Inoue K. Scavenger receptor-mediated uptake and metabolism of lipid vesicles containing acidic phospholipids by mouse peritoneal macrophages. J. Biol. Chem. 265:1990;5226-5231.
109. Ghosh P.C., Bachawat B.K. Role of surface glycolipids natural or synthetic origin on the biodistribution of liposomes. J. Lipid Res. 2:1992;369.
110. Van Berkel Th.J. Receptor-dependent uptake of macromolecules by specific hepatic cells. Junginger H.E. Drug Targeting and Delivery: Concepts in Dosage Form Design. 1992;13-25 Ellis Horwood, London.
111. Lee K.D., Pitas R.E., Papahadjopoulos D. Evidence that the scavenger receptor is not involved in the uptake of negatively charged liposomes by cells. Biochim. Biophys. Acta. 1111:1992;1-6.
112. Rigotti A., Acton S.L., Krieger M. The class B scavenger receptor SR-B1 and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270:1995;16221-16224.
113. Acton S., Rigotti A., Landschultz K.T., Xu S., Hobbs H.H., Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. 271:1996;518-520.
114. Ottend E., Parthasarthy S., Sambrano G.R., Ramprasad M.P., Quehenberger O., Kondratenco N., Green S., Steinberg D. A macrophage receptor for oxidized low density lipoprotein distinct from the receptor for acetyl low density lipoprotein: partial purification and role in recognition of oxidatively damaged cells. Proc. Natl. Acad. Sci. USA. 92:1995;1391-1395.
115. Jinnouchi Y., Sano H., Negai R., Hakamata H., Kodama T., Suzuki H., Yoshida M., Ueda S., Horiuchi S. Glyoaldehyde-modified low density lipoprotein leads macrophages to foam cells via the macrophage scavenger receptor. J. Biochem. 123:1998;1208-1217.
116. van Vlijmen B.J., Rohlmann A., Page S.T., Bensadoun A., Bos J.S., van Berkel Th.J., Havekes L.M., Herz J. An extrahepatic receptor-associated protein-sensitive mechanism is involved in the metabolism of triglyceride-rich lipoproteins. J. Biol. Chem. 274:1999;35219-35226.
117. Bijsterbosch M.K., van de Bilt H., van Berkel Th.J. Specific targeting of a lipophilic prodrug of iododeoxyuridine to parenchymal liver cells using lactosylated reconstituted high density lipoprotein particles. Biochem. Pharmacol. 52:1996;113-121.
118. de Vrueh R.L., Rump E.T., Sliedregt L.A., Biessen E.A., van Berkel T.J., Bijsterbosch M.K. Synthesis of a lipophilic prodrug of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and its incorporation into a hepatocyte-specific lipidic carrier. Pharm. Res. 16:1999;1179-1185.
119. D. Samain, J.L. Bec, E. Coben, R. Nguyen, M. Peyrot, Particulate vectors useful for transport of molecules with biological activity and process for preparation, PCT/FR89/000229, 1989.
120. Peyrot M., Sautereau A.M., Rabanel J.M., Nguyen F., Tocanne J.F., Samain D. Supramolecular biovectors (SMBV): a new family of nanoparticulate drug delivery systems. Synthesis and structural characterization. Int. J. Pharm. 102:1994;25-33.
121. De Miguel I., Ioualalen K., Bonnefous M., Peyrot M., Nguyen F., Cervilla M., Soulet N., Dirson R., Rieumajou V., Imbertie L. Synthesis and characterization of supramolecular biovector (SMBV) specifically designed for the entrapment of ionic molecules. Biochim. Biophys. Acta. 1237:1995;49-58.
122. Berton M., Sixou S., Kravtzoff R., Dartigues C., Imbertie L., Allal C., Favre G. Improved oligonucleotide uptake and stability by a new drug carrier, the Supra Molecular Bio Vector (SMBV). Biochim. Biophys. Acta. 1355:1997;7-19.
123. Allal C., Sixou S., Kravtzoff R., Soulet N., Soula G., Favre G. SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression. Br. J. Cancer. 77:1998;1448-1453.
124. Castignolles N., Betbeder D., Ioualalen K., Merten O., Leclerc C., Samain D., Penn P. Stabilization and enhancement of interleukin-2 in vitro bioactivity by new carriers: supramolecular biovectors. Vaccine. 12:1994;1413-1418.
125. Jaitely V., Vyas S.P. Supramolecular biovectors: development and characterization. J. Drug Targeting. 6:1999;315-322.
126. de Smidt P.C., Van Berkel Th.J.C. Prolonged serum half-life of antineoplastic drugs by incorporation into low-density lipoproteins. Cancer Res. 50:1990;7476-7482.
127. Versluis A.J., Rump E.T., Rensen P.C., Van Berkel Th.J., Bijsterbosch M.K. Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm. Res. 15:1998;531-537.
128. Ginsburg G.S., Small D.M., Atkinson D. Microemulsions of phospholipids and cholesterol esters: protein free models of low-density lipoprotein. J. Biol. Chem. 257:1982;8216-8227.
129. Ginsburg G.S., Walsh M.T., Small D.M., Atkinson D. Reassembled plasma low-density lipoproteins: phospholipid-cholesterol ester-apoprotein B complex. J. Biol. Chem. 259:1984;6667-6673.
130. Lundberg B., Hong K., Papahadjopoulos D. Conjugation of apolipoprotein B with liposomes and targeting to cells in culture. Biochim. Biophys. Acta. 1149:1993;305-312.
131. Maranhao R.C., Cesar T.B., Pedroso-Mariani S.R., Hirata M.H., Mesquita C.H. Metabolic behavior in rats of a non-protein microemulsion resembling low-density lipoprotein. Lipids. 28:1993;691-696.
132. Maranhao R.C., Garicochea B., Silva E.L., Dorlhiac-Llacer P., Cadena S.M.S., Coelho I.J.C., Menegheti J.C., Pileggi F.J.C., Chamone D.A.F. Plasma kinetics and biodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res. 54:1994;4660-4666.
133. Roerdink F., Wassef N.M., Richardson E.C., Alving C.R. Effect of negatively charged lipids on phagocytosis of liposomes opsonized by complements. Biochim. Biophys. Acta. 734:1983;33-39.
134. Klimov A.N., Korovkin B.F., Kuznetsov A.S., Popov I.N. Apolipoprotein B of plasma lipoproteins incorporated in liposomes: immunological properties and organ distribution when administered to rabbits. Byull. Eksp. Biol. Med. 96:1983;47.
135. Rensen P.C., van Dijk M.C., Havenaar E.C., Bijsterbosch M.K., Kruijt J.K., van Berkel T.J. Selective liver targeting of antivirals by recombinant chylomicrons - a new therapeutic approach to hepatitis B. Nat. Med. 1:1995;221-225.
136. Rensen P.C., Herijgers N., Netscher M.H., Meskers S.C.J., Van Eck M., van Berkel Th.J. Particle size determines the specificity of apoE-containing triglyceride-rich emulsions for the LDL-receptor versus hepatic remnant receptors in vivo. J. Lipid Res. 38:1997;1070-1084.
137. Rensen P.C., Oosten M., Bilt E., Eck M., Kuiper J., Berkel Th.J. Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats in vivo. J. Clin. Invest. 99:1997;2438-2445.
138. Rensen P.C., Schiffelers R.M., Versluis A.J., Bijsterbosch M.K., Meuwissen M.E.M.J., van Berkel Th.J. Human recombinant apolipoprotein E-enriched liposomes can mimic low density lipoproteins as carriers for the site-specific delivery of antitumor agents. Mol. Pharmacol. 52:1997;445-455.
139. Versluis A.J., Rensen P.C., Rump E.T., van Berkel Th.J., Bijsterbosch M.K. Low density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br. J. Cancer. 78:1998;1607-1614.
140. Versluis A.J., Rump E.T., Rensen P.C., van Berkel Th.J., Bijsterbosch M.K. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J. Pharmacol. Exp. Ther. 289:1999;1-7.
141. de Smidt P.C., Versluis A.J., van Berkel Th.J. Properties of incorporation, redistribution and integrity of porphyrin-LDL complexes. Biochemistry. 32:1993;2916-2922.
142. de Smidt P.C., Le Doan T., De Falco S., van Berkel Th.J. Association of antisense oligonucleotides with lipoproteins prolongs the plasma half life and modifies the tissue distribution. Nucleic Acids Res. 19:1991;4695-4700.
143. de Vries H.E., Moor A.C., Dubbelman T.M., van Berkel Th.J., Kuiper J. Oxidized low-density lipoprotein as a delivery system for photosensitizers: implications for photodynamic therapy of atherosclerosis. J. Pharmacol. Exp. Ther. 289:1999;528-534.
144. Naim J.O., Hinshaw J.R., van Oss C.J. The lack of antigenicity of tuftsin: a naturally occurring phagocytosis stimulating tetrapeptide. Immunol. Invest. 18:1989;817-824.
145. Dagan S., Tzehoval E., Fridkin M., Feldman M. Tuftsin and tuftsin conjugates potentiate immunogenic processes: effects and possible mechanisms. J. Biol. Response Mod. 6:1987;625-636.
146. Bhakuni V., Gupta C.M. Interactions of tuftsin with bovine serum albumin. FEBS Lett. 205:1986;347-350.
147. Naim J.O., van Oss C.J. The generation of antibody in mice to tuftsin: a naturally occurring phagocytosis stimulating tetrapeptide. Immunol. Invest. 20:1991;351-364.
148. Singhal A., Bali A., Jam R.K., Gupta C.M. Specific interactions of liposomes with PMN leukocytes upon incorporating tuftsin in their bilayers. FEBS Lett. 178:1984;109-113.
149. Gupta C.M., Pun A., Jam R.K., Bali A., Anand N. Protection of mice against Plasmodium berghei infection by a tuftsin derivative. FEBS Lett. 205:1986;351-354.
150. Guru P.Y., Agrawal A.K., Singhal U.K., Singhal A., Gupta C.M. Drug targeting in Leishmania donovani infections using tuftsin-bearing liposomes as drug vehicles. FEBS Lett. 245:1989;204-208.
151. Owais M., Ahmed I., Krishnakumar B., Jam R.K., Bachhawat B.K., Gupta C.M. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis. FEBS Lett. 326:1993;56-58.
152. Agarwal A.K., Kandpal H., Gupta H.P., Singh N.B., Gupta C.M. Tuftsin-bearing liposomes as rifampin vehicles in treatment of tuberculosis in mice. Antimicrob. Agents Chemother. 38:1994;588-593.
153. Kubo S., Rodriguez T. Jr., Roh M.S., Oyedeji C., Romsdahl M.M., Nishioka K. Stimulation of phagocytic activity of murine Kupffer cells by tuftsin. Hepatology. 19:1994;1044-1049.
154. Kumar P., Biswas S., Rao D.N. Potentiation of immune response against the RESA peptides of Plasmodium falciparum by incorporating a universal T-cell epitope (CS.T3) and an immunomodulator (polytufisin), and delivery through liposomes. Microbiol. Immunol. 43:1999;567-576.
155. Rosen M., Fischer D., Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46:1998;255-263.
156. Widder K., Marino P., Morris R., Seneyi A. Targeting antineoplastic agents using magnetic albumin microspheres. Goldberg E.P. Targeted Drugs. 1983;153-200 Wiley, New York.
157. Kamps J.A.A.M., Morselt H.W.M., Swart P.J., Wilkens M., Meijer D.K.F., Scherphof G.L. Targeting of liposomes to non-parenchymal liver cells by means of covalently coupled anionized albumins. J. Liposome Res. 69:1996;255.
158. Kamps J.A.A.M., Swart P.J., Morselt H.W.M., Pouwels R., de Bethune M.P., de Clercq E., Meijer D.K.F., Scherphof G.L. Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity. Biochim. Biophys. Acta. 1278:1996;183-190.
159. Tardi P.G., Swartz E.N., Harasym T.O., Cullis P.R., Bally M.B. An immune response to ovalbumin covalently coupled to liposomes is prevented when the liposomes used contain doxorubicin. J. Immunol. Methods. 210:1997;137-148.
160. Jansen R.W., Molema G., Pauwels R., Schols D., De Clercq E., Meijer D.K. Potent in vitro anti-human immunodeficiency virus-1 activity of modified human serum albumins. Mol. Pharmacol. 39:1991;818-823.
161. Jansen R.W., Olinga P., Harms G., Meijen D.K. Pharmacokinetic analysis and cellular distribution of the anti-HIV compound succinylated human serum albumin (Suc-HSA) in vivo and in the isolated perfused rat liver. Pharm. Res. 10:1993;1611-1614.
162. Ghetie V., Slaughter C., Wheeler H.T., Uhr J.W., Vietta E.S. CD4 peptide-protein conjugates, but not recombinant gp 120 from the human immunodeficiency virus in the presence of serum from AIDS patients. Proc. Natl. Acad. Sci. USA. 88:1991;5690-5693.
163. Curtis B.M., Scharnowske S., Watson A.J. Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp 120. Proc. Natl. Acad. Sci. USA. 89:1992;8536-8560.
164. Fujita T., Nishikawa M., Ohtsubo Y., Ohno J., Takakuna Y., Sezaki H., Hasbida M. Control of in vivo fate of albumin derivative utilizing combined chemical modification. J. Drug Targeting. 2:1994;157-165.
165. Sutherland R., Delia D., Schneider C., Newman R., Kemshead J., Greaves M. Ubiquitos cell surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Acad. Sci. USA. 78:1980;4515-4519.
166. Fishman J.B., Rubin J.B., Handrahan J.V., Connor J.R., Fine R.E. Receptor mediated transcytosis of transferrin across the blood-brain barrier. J. Neurosci. Res. 18:1987;299-304.
167. Wagner E., Zenke M., Cotton M., Beug H., Birnstiel M.L. Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA. 87:1990;3410-3414.
168. Wagner E., Zatloukal K., Cotton M., Kinlappos H., Mechtler K., Cuniel D.T. Coupling of adenovirus to transfenin-polylysine/DNA complexes greatly enhances receptor mediated gene delivery and expression of transfected genes. Proc. Natl. Acad. Sci. USA. 89:1992;6099-6103.
169. Tanaka T., Kaneo Y., Miyashita M. Synthesis of transferrin-Mitomycin C as a receptor-mediated drug targeting system. Biol. Pharm. Bull. 19:1996;774-777.
170. Munns J., Yaxley J., Coomen J., Lavin M.F., Gardinger R.A., Watters D. Evaluation of the potential of transferrin-adriamycin conjugates in the treatment of bladder cancer. Br. J. Urol. 82:1998;284-289.
171. Park E., Starzyk R.M., McGrath J.P., Lee T., George J., Schultz A.J., Lynch P., Putney S.D. Production and characterization of fusion proteins containing transferrin and nerve growth factor. J. Drug Targeting. 6:1998;53.
172. Uike H., Sakakibara R., Iwanaga K., Ide M., Ishiguro M. Efficiency of targeted gene delivery of ligand-poly-L-lysine hybrids with different crosslinks. Biosci. Biotechnol. Biochem. 62:1998;1247-1252.
173. Stavridis J.C., Deliconstantinos G., Psallidopoulos M.C., Armenakas N.A., Hadjiminas D.J., Hadjiminas J. Construction of transferrin-coated liposomes for in vivo transport of exogenous DNA to bone marrow erythrocytes in rabbits. J. Exp. Cell Res. 164:1986;568-572.
174. Hege K.M., Daleke D.L., Waldmann T.A., Matthay K.K. Comparison of anti-Tac and anti-transferrin receptor-conjugated liposomes for specific drug delivery to adult T-cell leukemia. Blood. 74:1989;2043-2052.
175. Egea M.A., Garcia M.L., Alsina M.A., Reig F. Coating of liposomes with transferrin: physicochemical study of the transferrin-lipid system. J. Pharm. Sci. 83:1994;169-173.
176. Ishida O., Maruyama K. Transferrin conjugated PEG-liposomes as intracellular targeting carrier for tumor therapy. Nippon Rinsho. 56:1998;657-662.
177. Yoshikawa T., Pardridge W.M. Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor. J. Pharmacol. Exp. Ther. 263:1992;897-903.
178. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc. Natl. Acad. Sci. USA. 93:1996;14164-14169.
179. Watanabe N., Sato Y., Yamauchi N., Nitsu Y. Gene delivery into human cancer cells via transferrin receptor. Nippon Rinsho. 56:1998;724-730.
180. Penichet M.L., Kang Y.S., Pardridge W.M., Morrison S.L., Shin S.U. An antibody-avidin fusion protein specific for the transferrin receptor serves as a delivery vehicle for effective brain targeting: initial applications in anti-HIV antisense drug delivery to the brain. J. Immunol. 163:1999;4421-4426.
181. Li J.Y., Sugimura K., Jboado R., Lee H.J., Zhang C., Duebel S., Pardridge W. Genetically engineered brain drug delivery vectors: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptividin fusion gene and protein. Protein Eng. 12:1999;787-796.
182. Kang Y.S., Bickel U., Pardridge W.M. Pharmacokinetics and saturable
183. Pardridge W.M., Boado R.J., Kang Y.S. Vector-mediated delivery of a polyamide (’peptide’) nucleic acid analogue through the blood brain barrier in vivo. Proc. Natl. Acad. Sci. USA. 92:1995;5592.
184. Rothberg K.G., Ying Y.S., Kolhouse J.F., Kamen B.A., Anderson R.G. The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway. J. Cell Biol. 110:1990;637-649.
185. Anderson R.G.W. Potocytosis of small molecules and ions by caveolae. Trends Cell Biol. 3:1993;69-72.
186. Lisanti M.P., Scherer P.E., Vidugiriene J., Tang Z.L., Hermanowski-Vesatka A., Tu Y.H., Cook R.F., Sergiacomo M. Characterization of caveolin-rich membrane domains from an endothelial-rich source. J. Cell Biol. 126:1994;111.
187. Wu M., Fan J., Gunning W., Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J. Membr. Biol. 159:1997;137.
188. Ross J.F., Chaudhury P.K., Ratnam M. Differentiation regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Cancer. 73:1994;2432-2443.
189. Gabizon A.T., Horowitz D., Goren D., Tzemach D., Mondelbaum-Shavit F., Qazen M.M., Zalipsky S. Targeting folate receptor with folate linked to the extremities of poly (ethylene glycol)-grafted liposomes: in vivo studies. Bioconjugate Chem. 10:1999;289-298.
190. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 269:1994;3198-3204.
191. Lee R.J., Low P.S. Folate-mediated tumor-cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233:1995;134-144.
192. Vogel K., Wang S., Lee R.J., Chemielewski J., Low P.S. Peptide-mediated release of folate-targeted liposome contents from endosomal compartments. J. Am. Chem. Soc. 118:1996;1581.
193. Lai J.Y. Effect of lipid composition on insulin-mediated fusion of small unilamellar liposomes: a kinetic study. J. Pharm. Sci. 77:1988;432-437.
194. Weissner J.H., Hwang K.J. Binding of insulin to external surface of liposomes. Effect of surface curvature, temperature, and lipid composition. Biochim. Biophys. Acta. 689:1982;490-498.
195. Tokihiro K., Irie T., Uekama K. Varying effects of cyclodextrin derivatives on aggregation and thermal behavior of insulin in aqueous solution. Chem. Pharm. Bull. Tokyo. 45:1997;525-531.
196. Sui S.F., Urumow T., Sachmann E. Interaction of insulin receptors with lipid bilayers and specific and non-specific binding of insulin to supported membranes. Biochemistry. 27:1988;7463-7469.
197. Pederson T.B., Frokjaer S., Mouritesen O.G., Jorgensen K. Phase behavior and lipid-membrane structure of phospholipid-glycosphingolipid liposomes and the thermal unfolding of insulin. J. Liposome Res. 9:1999;261-274.
198. Shah D., Shen W.C. Transcellular delivery of an insulin-transferrin conjugate in enterocyte-like Caco-2 cells. J. Pharm. Sci. 85:1996;1306-1311.
199. Tsai Y.J., Rottero A., Chow D.D., Hwang K.J., Lee V.H., Zhu G., Chan K.K. Synthesis and purification of NBl-palmitoyl insulin. J. Pharm. Sci. 86:1997;1264-1268.
200. Pierre E.J., Perez-Polo J.R., Mitchell A.T., Matin S., Foyt H.L., Herndon D.N. Insulin-like growth factor-I liposomal gene transfer and systemic growth hormone stimulate wound healing. J. Burn Care Rehabil. 18:1997;287-291.
201. Pardridge W.M., Kang Y.S., Bucialk J.L., Yang J. Human insulin receptor monoclonal antibody undergoes high affinity binding to human brain capillaries in vitro and rapid transcytosis through the blood-brain barrier in vivo in the primate. Pharm. Res. 12:1995;807-816.
202. Wu D., Yang J., Pardridge W.M. Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptors. J. Clin. Invest. 100:1997;1804-1812.
203. Xu Y.H., Richert N., Ito S., Merlino G.T., Pasten I. Characterization of epidermal growth factor receptor gene expression in malignant and normal cell lines. Proc. Natl. Acad. Sci. USA. 81:1984;7308.
204. Chen J., Gamou S., Takayanagi A., Ohtake Y., Ohtsubo M., Shimizu N. Targeted in vivo delivery of therapeutic gene into experimental squamous cell carcinoma using anti-EGF receptor antibody: immunogen approach. Hum. Gene Ther. 9:1998;2673-2681.
205. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318.
206. Deguchi Y., Kurihara A., Pardridge W.M. Retention of biologic activity of human epidermal growth factor following conjugation to a blood-brain barrier drug delivery vector via an extended poly(ethylene glycol) linker. Bioconjugate Chem. 10:1999;32-37.
207. 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjugate Chem. 10:1999;502-511.
208. Granholm A.C., Backman C., Bloom F., Ebendal T., Gerhardt G., Hoffer B., Mackerlova L., Olson L., Soderstrom S., Walus L.R., Friden P.M. NGF and anti-transferrin receptor antibody conjugate: short and long term effects on survival of cholinergic neurons in intraocular septal transplants. J. Pharmacol. Exp. Ther. 268:1994;448-459.
209. Backman C., Biddle P.T., Ebendal T., Friden P.M., Gerhardt G.A., Henry M.A., Mackerlova L., Soderstrrom S., Stromberg I., Walus L., Hoffer B.J., Granholm A.C. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo. Exp. Neurol. 132:1995;1-15.
210. Takayanagi A., Chen J., Gamou S., Shimizu N. Targeting delivery of therapeutic genes using monoclonal antibody: immunogene approach. Nippon Rinsho. 56:1998;731-736.
211. Rosenberg M.B., Breakfield X.O., Hawrot E. Targeting of liposomes to cells bearing nerve growth factor receptors mediated by biotinylated nerve growth factor. J. Neurochem. 48:1987;865.
212. Niell H.B., Mauer A.M., Rademacher D. Cytotoxic effects of alpha- and gamma-interferon and tumor necrosis factor in human bladder tumor cell lines. Urol. Res. 22:1994;247-250.
213. Nakajima Y., DelliPizzi A., Mallouh C., Ferreri N.R. Effect of tumor necrosis factor-alpha and interferon-gamma on the growth of human prostate cancer cell lines. Urol. Res. 23:1995;205-210.
214. Burrow F.J., Tazzari P., Amlot P., Gajdar A.F., Derbyshire E.J., King S.W., Vitetta E.S., Thorpe P.E. Endoglin is an endothelial cell proliferation marker that is selectively expressed in tumor vasculature. Clin. Cancer Res. 1:1995;1623-1634.
215. Tabata Y., Noda Y., Matsui Y., Ikada Y. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination. J. Control. Release. 59:1999;187-196.
216. Tabata Y., Matsui Y., Ikada Y. Growth factor release from amylopectin hydrogel based on copper coordination. J. Control. Release. 56:1998;135-148.
217. Jones B.B., Petkovich M. Targeting transcription through nuclear receptors. Cancer Res. 2:1996;156-168.
218. Dachs G.U., Dougherty G.J., Stratford I.J., Chaplin D.J. Targeting gene therapy to cancer: a review. Oncol. Res. 9:1997;313-325.
219. McElvany K.D., Carlson K.E., Katzenellenbogen J.A., Welch M.J. Factors affecting the target site uptake selectivity of estrogen radiopharmaceuticals: serum binding and endogenous estrogens. J. Steroid Biochem. 18:1983;635-641.
220. Casy A.F., Parfitt R.T. Opioid Analgesics: Chemistry and Receptors. 1986;Plenum Press, New York.
221. Ringrose P.S., Humphrey M.J. Peptides as targets and carriers. Gregoriadis G., Senior J., Poste G. Targeting of Drugs With Synthetic Systems. NATO ASI Series. Series A: Life Sciences. Vol. 113:1986;65-84 Plenum press, London.
222. Shimohigashi Y., Costa T., Matusuura S., Chen H.C., Rodbard D. Nature. 297:1982;333-335.
223. Eberle A.N., Kriwaczek V.M., Schulster D. Perspectives in peptide chemistry. Eberle A.N., Geiger R., Wieland T. Peptide Chemistry. 1981;407-422 Karger, Basel.
224. Sasaki-Yagi Y., Kimura S., Ueda H., Imanishi Y. Binding of enkephalin/dextran conjugate to opioid receptors. Int. J. Pept. Protein Res. 43:1994;219-224.
225. Tetsui S., Kimura S., Imanishi Y. Peptide Chemistry. Yanahaira N. 1992;381-383 ESCOM, Leiden.
226. Zhao J., Kimura S., Imanishi Y. Multivalent ligand system carrying enkephalin and neurotensin coimmobilized on liposomes. J. Pept. Sci. 2:1996;245-251.
227. Ogawa Y., Kawahara H., Yagi N., Kodaka M., Tomohiro T., Okada T., Konakahara T., Okuno H. Synthesis of a novel lipopeptide with alpha-melanocyte-stimulating hormone peptide ligand and its effect on liposome stability. Lipids. 34:1999;387-394.
228. Cremaschi D., Porta C., Ghirardelli R. Different kinds of polypeptides and polypeptide-coated nanoparticles are accepted by the selective transcytosis shown in the rabbit nasal mucosa. Biochim. Biophys. Acta. 1416:1999;31-38.
229. Bloemen P.G.M., Henricks P.A.J., van Bloois L., van den Tweel M.C., Blqem A.C., Nijkamp F.P., Crommelin D.J.A., Storm G. Adhesion molecules: a new target for immunoliposome-mediated drug delivery. FEBS Lett. 357:1995;140-144.
230. Sun Q.H., De Lisser H.M., Zukowski M.M., Paddock C., Albelda S.M., Newman P.J. Individually distinct Ig homology domains in PECAM-1 regulate homophilic binding and modulate receptor affinity. J. Biol. Chem. 271:1996;11090-11098.
231. Mareel M., Berx F., Van Roy F., Bracke M. Cadherin/catenin complex: a target for antiinvasive therapy. J. Cell. Biochem. 61:1996;524-530.
232. Ruoslahti E. RGD and other recognition sequences for integrins. Annu. Rev. Cell Dev. Biol. 12:1996;697-715.
233. Bates R.C., Lincz L.F., Burns G.F. Involvement of integrins in cell survival. Cancer Metastasis Rev. 14:1995;191-203.
234. Varner J.A., Brooks P.C., Cheresh D.A. Review: the integrins alpha v beta 3: angiogenesis and apoptosis. Cell Adhes. Commun. 3:1995;367-374.
235. Barbas C.F., Languino L.R., Smith J.W. High-affinity self-reactive antibodies by design and selection: targeting the integrin ligand binding site. Proc. Natl. Acad. Sci. USA. 90:1993;10003-10007.
236. Drake C.J., Cheresh D.A., Little C.D. An antagonist of integrin alpha v beta 3 prevents maturation of blood vessels during embryo neovascularization. J. Cell Sci. 108:1995;2655-2661.
237. Sipkins D.A., Brooks P.C., Cheresh D.A., Li K.P.C., Bednarski M.D. Development of a new angiogenesis-specific liposome particle for use in diagnostic imaging and drug delivery. AACR Proceedings:1996;American Association of Cancer Research, Washington, DC.
238. D’Souza S.E., Ginsberg M.H., Plow E.F. Arginyl-glycyl-aspartic acid (RGD): a cell adhesion motif. Trends Biochem. Sci. 16:1991;246-250.
239. Saiki I., Koike C., Obata A., Fuji H., Murata J., Kiso M., Hasegawa A., Komazawa H. Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor cell arrest in lungs followed by extravasation. Int. J. Cancer. 65:1996;833-839.
240. Nishiya T., Sloan S. Interaction of RGD liposomes with platelets. Biochem. Biophys. Res. Commun. 224:1996;242-245.
241. Zalipsky S., Puntambekar B., Boulikas P., Engbers C.M., Woodle M.C. Peptide attachment to extremities of liposomal grafted PEG chains: preparation of the long-circulating form of laminin pentapeptide, YIGSR. Bioconjugate Chem. 6:1995;705-708.
242. Rosen S.D., Bertozzi C.R. The selectins and their ligands. Curr. Opin. Cell Biol. 6:1994;663-673.
243. Foxall C., Watson S.R., Dowbenko D., Fennie C., Lasky L.A., Kiso M., Hasegawa A., Asa D. The three members of the selectin receptor family recognize a common carbohydrate epitope, the sialyl Lewis (X) oligosaccharide. J. Cell Biol. 117:1992;895-902.
244. Oku N., Tokudome Y., Koike C., Nishikawa N., Mon H., Saiki I., Okada S. Liposomal Arg-Gly-Asp analogues effectively inhibit metastatic B16 melanoma colonization in murine lungs. Life Sci. 58:1996;2263-2270.
245. Kumagai K., Ikuta K. Aloia R.C., Curtain C.C. Membrane Interaction of HIV. 1992;Wiley-Liss, Washington, DC.
246. Slepushkin V.A., Salem I.I., Andreev S.M., Dazin P., Duzgunes N. Targeting of liposomes to HIV-1 infected cells by peptides derived from the CD4 receptor. Biochem. Biophys. Res. Commun. 227:1996;827-833.
247. Annemiek J.M.L., van Rensen A.J.M.L., Wauben M.H.M., Stulemeyer M.C.G., van Eden W., Cromelin D.J.A. Liposomes with incorporated MHC class II/peptide complex as antigen presenting vesicles for specific T cell activation. Pharm. Res. 16:1999;198-204.
248. Noguchi Y., Noguchi T., Sato T., et al. Priming of in vivo and in vitro anti-human T lymphotropic virus type 1 cellular immunity by virus-related protein constituted into liposomes. J. Immunol. 146:1991;3599.
249. Toda S., Ishii N., Okada E., Kusakabe K.I., Arai H., Hamajima K., Gorai I., Nishioka K. HIV-1 specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-γ-antibody. Immunology. 92:1997;111.
250. Fukusawa M., Shimizu Y., Shikata K., Nakata M., Sakakibara R., Yamamoto N., Hatanaka M., Mizouchi T. Liposome oligomannose-coated with neoglycolipid, a new candidate for a safe adjuvant for induction of CD8+ cytotoxic T lymphocytes. FEBS Lett. 441:1998;353-356.
251. Schreier H., Ausborn M., Gunther S., Weissig V., Chander R. (Patho)physiologic pathways to drug targeting: artificial viral envelope. J. Mol. Recogn. 8:1995;59-62.
252. Wright S., Huang L. Antibody-directed liposomes as drug-delivery vehicles. Adv. Drug Deliv. Rev. 3:1989;343-389.
253. Norley S.G., Huang L., Rouse B.T. Targeting of drug loaded immunoliposomes to herpes simplex virus infected corneal cell, and effective means of inhibiting virus replications in vitro. J. Immunol. 136:1986;681-685.
254. Khaw B.A., Torchilin V.P., Vural I., Narula J. Plug and seal: prevention of hypoxic cardiocyte death by sealing membrane lesions with antimyosin-liposomes. Nat. Med. 1:1995;1195.
255. Cho B.K., Roy E.J., Patrik T.A., Kranz D.M. Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells. Bioconjugate Chem. 8:1997;338.
256. Begnet R.H.J., Verhaar M.J., Chester K.A., Casey J.L., Green A.J., Napier M.P., Hope-Stone L.D., Cushen N., Keep P.A., Johnson C.J. Clinical evidence of effective tumor targeting based on a single chain Fv antibody selected from a combinatorial library. Nat. Med. 2:1996;979.
257. Epstein A.L., Khawli L.A., Hornick J.L., Taylor C.R. Identification of a monoclonal antibody, TV-1, directed against the basement membrane of tumor vessels, and its use to enhance the delivery of macromolecules to tumors after conjugation with interleukin-2. Cancer Res. 55:1995;2673-2680.
258. Depraetere S., Joniau M. Potentiation of tumor necrosis factor-mediated cytotoxicity on human myeloid cell lines: effects of interferons versus dimethylsulphoxide. Leuk. Res. 19:1995;803.
259. Yang J., Cleland J.L. Factors affecting the in vitro release of recombinant human interferon-gamma (rhIFN-gamma) from PLGA microspheres. J. Pharm. Sci. 86:1997;908-914.
260. Foldvari M., Baca-Estrada M.E., He Z., Hu J., Attah-Poku S., King M. Dermal and transdermal delivery of protein pharmaceuticals: lipid-based delivery systems for interferon alpha. Biotechnol. Appl. Biochem. 30:1999;129-137.
261. Ishihara H., Hara T., Aramaki Y., Tsuchiya S., Hosoi K. Preparation of asialofetuin-labeled liposomes with encapsulated human interferon-gamma and their uptake by isolated rat hepatocytes. Pharm. Res. 7:1990;542-546.
262. Mizuno M., Yoshida J., Sugita K., Inoue I., Seo H., Hayashi Y., Koshizaka T., Yagi K. Growth inhibition of glioma cells transfected with the human beta-interferon gene by liposomes coupled with a monoclonal antibody. Cancer Res. 50:1990;7826-7829.
263. Xi K., Tabata Y., Uno K., Yoshimoto M., Kishida T., Sokawa Y., Ikada Y. Liver targeting of interferon through pullulan conjugation. Pharm. Res. 13:1996;1846-1850.
264. Weissman A.M., Harford J.B., Svetlik P.B., Leonard W.L., Depper J.M., Waldmann T.A., Greene W.C., Klausner R.D. Only high affinity receptors for interleukin 2 mediate internalization of ligand. Proc. Natl. Acad. Sci. USA. 83:1986;1463-1466.
265. Totpal K., Aggarwal B.B. Interleukin 4 potentiates the antiproliferative effects of tumor necrosis factor on various tumor cell lines. Cancer Res. 51:1991;4266-4271.
266. Dittrich E. Identification of a region within the cytoplasmic domain of the interleukin-6 (IL-6) signal transducer gp 130 important for ligand-induced endocytosis of the IL-6 receptor. J. Biol. Chem. 269:1994;19014-19020.
267. Katre N., Knauf M., Laird W. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in murine Meth A sarcoma model. Proc. Natl. Acad. Sci. USA. 84:1987;1487-1491.
268. Anderson P., Vilcek J., Weissmann G. Entrapment of human leukocyte interferon in the aqueous interstices of liposomes. Infect. Immun. 31:1981;1099-1103.
269. Sato J., Hamaguchi N., Doken K., Gotoh K., Ootsu K., Iwasa S., Ogawa Y., Toguchi H. Enhancement of anti-tumor activity of recombinant interleukin-2 (rIL-2) by immunocomplexing with a monoclonal antibody against rIL-2. Biotherapy. 6:1993;225-231.
270. Tsunoda S., Tsutsumi Y., Mayumi T. Molecular design of polymer-conjugated cytokines and its application for drug delivery system. Nippon Rinsho. 56:1998;573-578.
271. Kedar E., Rutkowski Y., Braun E., Emanuel N., Barenholz Y. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes. J. Immunother. Emphasis Tumor Immunol. 16:1994;47-59.
272. Konigsberg P.J., Godtel R., Kissel T., Richer L.L. The development of IL-2 conjugated liposomes for therapeutic purposes. Biochim. Biophys. Acta. 1370:1998;243-251.
273. Okuno K., Nakamura K., Tanaka A., Yachi K., Yasutomi M. Hepatic immunopotentiation by galactose-entrapped liposomal IL-2 compound in the treatment of liver metastases. Surg. Today. 28:1998;64-69.
274. Nakamura K., Okuno K., Hirohata T., Shigeoka H., Jinnai H., Yasutomi M. Selective effectiveness of galactose-containing liposome IL-2 on liver lymphocytes. Gan To Kagaku Ryoho. 21:1994;2105-2107.
275. Okada N., Miyamoto H., Yoshioka T., Katsume A., Saito H., Yorozu K., Ueda O., Itoh N., Mizuguchi H., Nakagawa S., Ohsugi Y., Mayumi T. Cytomedical therapy for IgG1 plasmacytosis in human interleukin-6 transgenic mice using hybridoma cells microencapsulated in alginate-poly(L)lysine-alginate membrane. Biochim. Biophys. Acta. 1360:1997;53-63.
276. Egilmez N.K., Jong Y.S., Iwanuma Y., Jacob J.S., Santos C.A., Chen F.A., Mathiowitz E., Bankert R.B. Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID model. Cancer Immunol. Immunother. 46:1998;21-24.
277. Horie K., Sakagami M., Kuramochi K., Hanasaki K., Hamana H., Ito T. Enhanced accumulation of Sialyl Lewis-Carboxymethyl pullulan conjugate in acute inflammatory lesion. Pharm. Res. 16:1999;314-320.